Celltrio Closes $15 Million Investment

<p><strong>FREMONT<&sol;strong> &&num;8212&semi; Celltrio&comma; a life sciences company delivering advanced automation solutions for cell culturing and cell &amp&semi; gene therapy&comma; announced the closing of a &dollar;15 million financial investment round led by Premier Partners&period;<&sol;p>&NewLine;<p>The new funding will accelerate the global commercialization of RoboCell®&comma; Celltrio’s flagship modular platform for fully automated&comma; sterile cell culturing and cell therapy manufacturing&period; Investment proceeds will be used to scale manufacturing capabilities&comma; expand commercial operations across North America&comma; Europe&comma; and Asia and fuel continued innovation of GMP-ready automation solutions for biopharma&comma; regenerative medicine&comma; and advanced research laboratories&period;<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;This investment marks a major milestone for Celltrio and validates our mission to streamline&comma; scale&comma; and standardize cell manufacturing through automation&comma;” said Charlie Duncheon&comma; CEO of Celltrio&period; &OpenCurlyDoubleQuote;We are thrilled to partner with Premier Partners&comma; who share our vision of transforming the future of cell-based therapies with next-generation automation solutions&period;”<&sol;p>&NewLine;<p>&OpenCurlyDoubleQuote;We are highly impressed by Celltrio’s customer traction and its differentiated intellectual property in cell culturing and cell &amp&semi; gene therapy automation&comma;” said Jay Song&comma; CEO of Premier Partners&period; &OpenCurlyDoubleQuote;We believe Celltrio is poised to become a category-defining leader&comma; delivering scalable&comma; sterile automation to laboratories and manufacturing facilities worldwide&period;”<&sol;p>&NewLine;